Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 22.21B P/E - EPS this Y 11.50% Ern Qtrly Grth 35.40%
Income -76M Forward P/E 14.21 EPS next Y 11.40% 50D Avg Chg -2.00%
Sales 14.81B PEG 3.47 EPS past 5Y -1.76% 200D Avg Chg -5.00%
Dividend 3.00% Price/Book 3.99 EPS next 5Y 4.07% 52W High Chg -29.00%
Recommedations 2.70 Quick Ratio 0.91 Shares Outstanding 509.35M 52W Low Chg 18.00%
Insider Own 0.37% ROA 3.34% Shares Float 505.48M Beta 0.63
Inst Own 92.49% ROE -0.96% Shares Shorted/Prior 9.68M/8.18M Price 43.91
Gross Margin 38.22% Profit Margin 17.93% Avg. Volume 5,278,919 Target Price 45.00
Oper. Margin 12.07% Earnings Date May 2 Volume 5,360,379 Change -2.42%
About Baxter International Inc.

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Baxter International Inc. News
04/12/24 Baxter's (BAX) New Injectables Aid Its Pharmaceutical Portfolio
04/12/24 Comfort Systems USA and Boeing have been highlighted as Zacks Bull and Bear of the Day
04/11/24 3 Medical Device Stocks With Solid Dividend Yield: CAH & Others
04/11/24 Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.
04/10/24 Baxter to Host First-Quarter 2024 Financial Results Conference Call for Investors
04/10/24 Reasons to Hold Baxter International (BAX) in Your Portfolio
04/10/24 Baxter Is Deeply Undervalued
04/05/24 Shareholders in Baxter International (NYSE:BAX) are in the red if they invested three years ago
04/02/24 Baxter's (BAX) Latest FDA Approval to Boost Infusion Therapy
04/01/24 Baxter Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy
03/27/24 Baxter to Host Annual Meeting of Stockholders in Virtual Format
03/26/24 Don't 'run away' from tech, but do broaden out: Strategist
03/13/24 Should You Hold Baxter International (BAX)?
03/06/24 Baxter to close Massachusetts site, lay off 59 people
03/05/24 Insider Sell: EVP, Chief HR Officer Jeanne Mason Sells 64,488 Shares of Baxter International ...
03/04/24 Baxter considers selling kidney care unit to private equity
02/29/24 Baxter to Present at Raymond James 45th Annual Institutional Investors Conference
02/24/24 It Might Not Be A Great Idea To Buy Baxter International Inc. (NYSE:BAX) For Its Next Dividend
02/23/24 20 Fastest Growing Biotech Companies in the US
02/21/24 Spectral Medical Announces Amendment and Extension of Exclusive Supply and Distribution Agreement With Baxter Healthcare Corporation
BAX Chatroom

User Image tarspro Posted - 23 hours ago

@Torp Or maybe $BAX?? Few others out there.

User Image ICUMaximGroupshortingICU Posted - 2 days ago

$BAX yo you guys please buy $ICU , we tired

User Image Torp Posted - 2 days ago

$ICU a lot of volume today for $BAX

User Image Youngandhappy Posted - 3 days ago

@WWladSMT @vitoi @KSTom No sell, no loss. Add! Thenadd! $BAX merger approacheth! MB

User Image Youngandhappy Posted - 4 days ago

@Codexxx The $BAX spin off makes the most sense here XXX. Schlorff and team are too long in the tooth to simply sit back while we plummet to the center of the earth without a plan near and dear to our hearts which takes this miraculous cure to the masses as quickly as possible. MB

User Image Youngandhappy Posted - 4 days ago

$ICU $NUWE $FMS $DVA $BAX CMO Dr. Kevin is a winner. Quelimmune SCD is a winner. The planet will soon be the biggest winner because of that combination. MB

User Image Aigner_Andreas Posted - 1 week ago

TF SELL $BAX at 39.57 : 39.61 BigCap 98% Shp 1.42 S 1.94 N 0.89 RSI 33.34% SRSI 0% ADXR 29.44 #stocks #trading #finance #market

User Image FutureOpt Posted - 1 week ago

$BAX $FMS $ICU They are giving us all the tips regarding a merger or a buyout. I was just about to post this 👇 Also check page 48 Load the boat!

User Image SideJobTrader Posted - 1 week ago

$ICU They didn't have to mention $FMS $BAX but they did? #MB

User Image Ricothetweko Posted - 1 week ago

$BAX Only .08cents from touching the 200sma on the daily chart. Looking for a bounce here back to 50sma. Stand By.

User Image Julian46 Posted - 1 week ago

$ICU $BAX

User Image 11thestate Posted - 1 week ago

$BAX Even if the deadline has passed you can still file for a late claim

User Image Youngandhappy Posted - 1 week ago

@Profitfire @Nmd_1980 $BAX, and how exactly are they involved in anything here. The sale of their Kidney business in July? To whom? They still own the spinoff, do they not? Davita buys it? Fresenius buys it? Please explain your hunches. TY. $NUWE $ICU MB, NS, MP

User Image Stock_Titan Posted - 2 weeks ago

$BAX Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S. https://www.stocktitan.net/news/BAX/baxter-expands-pharmaceuticals-portfolio-with-new-injectable-7jxpbhr5msdu.html

User Image Profitfire Posted - 2 weeks ago

$NUWE $ICU $DVA and $BAX there is something coming 🌚 who will merge with nuwe ?! I expecting a 100% merger run from this level with NUWE Remember with low volume trading a stock is falling… will recover fast with value trading 😏📈 patent news data updates are still good here some day we will turn up fast again 🙌

User Image Stock_Titan Posted - 2 weeks ago

$BAX Baxter to Host First-Quarter 2024 Financial Results Conference Call for Investors https://www.stocktitan.net/news/BAX/baxter-to-host-first-quarter-2024-financial-results-conference-call-vykvbpeddww5.html

User Image ICUMaximGroupshortingICU Posted - 3 weeks ago

$BAX $ICU mb

User Image 11thestate Posted - 3 weeks ago

$BAX pays $18M to investors who suffered losses because of its false statements. Claim submission info and details:https://11thestate.com/cases/baxter-fair-fund Who is eligible to get a payout? All persons who purchased or otherwise acquired shares of Baxter International common stock during the period from May 6, 2015, through October 23, 2019, inclusive.

User Image DonCorleone77 Posted - 3 weeks ago

$BAX FDA clears Baxter's Novum IQ LVP and dose IQ safety software Baxter International announced U.S. Food and Drug Administration FDA 510 k clearance of its Novum IQ large volume infusion pump LVP with Dose IQ Safety Software. Adding LVP modality to the Novum IQ Infusion Platform - which includes Baxter's syringe infusion pump with Dose IQ Safety Software, powered by the IQ Enterprise Connectivity Suite - enables clinicians to utilize a single, integrated system across a variety of patient care settings. Offering the Novum IQ LVP in the U.S. demonstrates Baxter's commitment to continued innovation in advancing infusion therapy. Heather Knight, executive vice president and group president, Medical Products and Therapies at Baxter, highlighted the customer-centric approach of the Novum IQ platform, emphasizing its role in helping to enhance care delivery. "Our goal, always, is to bring increased efficiency, safety and opportunity for informed decision-making to our customers..."

User Image Stock_Titan Posted - 3 weeks ago

$BAX Baxter Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy https://www.stocktitan.net/news/BAX/baxter-announces-u-s-fda-clearance-of-novum-iq-large-volume-infusion-ivdzhhjjd7zq.html

User Image Aznwactrackstar Posted - 03/29/24

$ICU this is the pic from $BAX site

User Image GoodTidings Posted - 03/29/24

$ICU $BAX True!!! But from Baxter perspective its the opposite!!! 😃😃😃💪💪💪💸💸💸

User Image steveboehm Posted - 03/29/24

$ICU $BAX And why would buyout need to happen before spinoff? Personally, I think the longer we can delay buyout the better

User Image John_Wick1234 Posted - 03/29/24

$BAX Rising Support Trendline

User Image GoodTidings Posted - 03/28/24

$ICU $BAX Maybe that new CEO is Kevin Chung or ICU Current CEO Eric Schlorff? 🤔🤔🤔

User Image GoodTidings Posted - 03/28/24

$ICU Maybe Yesterday buying Spree has to do with the $BAX strong BO speculation of SeaStar Medical!!! 🤔🤔🤔

User Image GoodTidings Posted - 03/28/24

$ICU $BAX The latest update on Baxter's kidney reorganization is that the company is moving forward with its restructuring plans and is still on track to spin off its kidney care business into a separate, publicly traded company by July 2024. The new company will be named **Vantive**¹². Baxter is also in the process of finalizing a search for a CEO to lead Vantive¹. Additionally, Baxter has been exploring strategic alternatives for its biopharma solutions unit, which has attracted significant interest¹. The restructuring aims to simplify operations and focus on improving outcomes for patients with kidney disease and other vital organ support through innovative technologies and services². Bron: Gesprek met Bing, 29-3-2024 (1) Baxter restructures, kidney care spinoff still planned for 2024. https://www.medtechdive.com/news/baxter-q1-earnings-kidney-spinoff-BAX/648794/. (2) Baxter - Baxter Announces Vantive as the Name of Proposed Kidney Care ....

User Image GoodTidings Posted - 03/28/24

$ICU $BAX The best time for Baxter to buyout SeaStar Medical is before Adult approval and before July 2024 when the new spinoff company is expected to be sold to the market!!! Before adult approval would benefit Baxter for buyout price and second it would need to buyout ICU anyways before July 2024 company spinoff and IPO!!!

User Image GoodTidings Posted - 03/28/24

$ICU $BAX For Baxter to sell a kidney spin off company on the NASDAQ stock exchange to make it a success it should be a complete proposition!!! ICU with breakthrough SCD device would make it a complete and attractive key sales proposition with a huge edge against any competitor in the market!!! Sales of $8 billion worth of stock could be a serious indicator of ICU BO preparations and reorganization!!! Hold on to your golden tickets cause interesting events are about to unfold!!! 🤔🤔🤔

User Image GoodTidings Posted - 03/28/24

$ICU The $BAX BO speculation is quite interesting and not far fetched... All kind of signs that point to serious Baxter interest... 1 - Baxter Sponsorship 2 - Perfect fit on Baxter CRRT device 3 - Inventor of SCD wearing Baxter shirt 4 - Baxter reorganization to spinoff a separate kidney focussed company for IPO on the stock market 5 - Sales of $8 billion worth of stock 🤔🤔🤔

Analyst Ratings
Citigroup Neutral Apr 3, 24
B of A Securities Neutral Mar 5, 24
Barclays Overweight Feb 12, 24
JP Morgan Neutral Feb 9, 24
Morgan Stanley Equal-Weight Dec 4, 23
JP Morgan Neutral Oct 31, 23
Citigroup Neutral Aug 21, 23
Barclays Overweight Aug 1, 23
Barclays Overweight Jul 31, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Mason Jeanne K SVP, Human Resources SVP, Human Resources Feb 14 Option 30.95 54,143 1,675,726 175,242 02/16/22
Mason Jeanne K SVP, Human Resources SVP, Human Resources Feb 14 Sell 85.15 54,143 4,610,276 121,099 02/16/22
Kunzler Jacqueline SVP, Chief Quality O.. SVP, Chief Quality Officer Jan 07 Option 30.95 2,215 68,554 8,341 01/11/22
HELLMAN PETER S Director Director Apr 07 Option 31.26 4,990 155,987 30,389 04/07/21